Nutex Health

The cash collections number from Q3 is staggering. Nutex pulled in 235 million dollars in actual cash from patients and insurers in the third quarter alone, up 258.8% from 65.5 million dollars a year earlier. Year to date collections hit 546 million dollars, nearly triple last year's pace. Patient volume also climbed 11.1% to 46,293 visits in the quarter. When real cash is showing up at this scale, it puts a meaningful floor under the story.

This isn't just one lever working. Patient visits grew 14% year to date to 140,135, and the company is actively expanding with new facilities like Archview ER in St. Louis and a relaunched Bayou City ER in Texas, with three to four more hospitals planned in 2026. Combine steady visit growth with dramatically higher cash per visit from better payer mix and arbitration wins, and you get the kind of operating leverage healthcare investors rarely see.

Nutex is still digging out of an accounting mess. The company told investors not to rely on its 2024 annual report or its first quarter 2025 numbers after finding errors tied to a 2022 merger earn-out. Nasdaq granted an extension to file the delayed second quarter 10-Q by December 12, 2025, and the third quarter filing will come even later. Until clean audited statements land, every headline number is technically preliminary and subject to change.

The collections surge leans heavily on out-of-network billing arbitration under the No Surprises Act. That framework can shift. A regulatory tweak, a court ruling, or a change in how insurers are forced to pay could compress margins fast. Add a 2.02 beta, ongoing short seller attention, and pending litigation, and this stock can swing 20% on any single headline. Position sizing matters here.